- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.07. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 29.06. | Xilio Therapeutics beruft Ben Harshbarger zum neuen Chief Legal Officer | 3 | Investing.com Deutsch | ||
| 29.06. | Xilio Therapeutics appoints Ben Harshbarger as chief legal officer | 4 | Investing.com | ||
| 29.06. | Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer | 656 | GlobeNewswire (Europe) | WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people... ► Artikel lesen | |
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.06. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.05. | Xilio Therapeutics reports Q1 results | 1 | Seeking Alpha | ||
| 12.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates | 559 | GlobeNewswire (Europe) | On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data... ► Artikel lesen | |
| 12.05. | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.05. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 17.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 | 1 | GlobeNewswire (USA) | ||
| 16.04. | Xilio Therapeutics appoints Cheryl Blanchard to board | 1 | Investing.com | ||
| 16.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 16.04. | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 23.03. | Xilio plans mid-2026 IND filing for cancer therapy XTX501 | 2 | Investing.com | ||
| 23.03. | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 23.03. | Xilio plant IND-Antrag für Krebstherapie XTX501 für Mitte 2026 | 2 | Investing.com Deutsch | ||
| 23.03. | Xilio Therapeutics, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 23.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results | 419 | GlobeNewswire (Europe) | XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,181 | +1,02 % | Valneva im Blickpunkt: Kann das VLA15 den Kurs wenden? | ||
| VIVOSIM LABS | 0,339 | -1,65 % | VivoSim Labs, INC. - S-1, General form for registration of securities | ||
| VIVORYON THERAPEUTICS | 1,160 | -1,28 % | Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026 | Vivoryon Therapeutics N.V. to Report H1 2026 Financial Resultsand Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026
Halle (Saale) / Munich, Germany, July... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 13,280 | +3,11 % | Sarepta Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TRAWS PHARMA | 0,460 | +2,27 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen | |
| VERASTEM | 4,939 | -1,89 % | Verastem doses first patient in lung cancer trial for VS-7375 | ||
| UNIQURE | 37,700 | -0,40 % | uniQure Inc.: uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update | ~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for the third quarter of 2026 ~
~ Topline four-year data from the Phase I/II study of AMT-130 expected... ► Artikel lesen | |
| TRINITY BIOTECH | 11,750 | +1,29 % | Trinity Biotech plc: Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology | - Strategic collaboration and equity investment will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intradermal drug delivery technology to develop... ► Artikel lesen | |
| ZAI LAB LTD ADR | 15,700 | -1,26 % | Zai Lab receives Orphan Drug status for ADC for neuroendocrine carcinomas | ||
| VOYAGER THERAPEUTICS | 2,634 | +0,38 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| TVARDI THERAPEUTICS | 1,230 | -0,81 % | Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 | ||
| XBIOTECH | 1,936 | +6,61 % | XBiotech Inc.: XBiotech startet klinische Phase-II-Studie zur Bewertung von Vilamakitug bei der Behandlung der aktiven axialen Spondyloarthritis | Der IND-Antrag für die V-SPINE-Studie hat die 30-tägige FDA-Prüfung ohne klinischen Stopp durchlaufen und ebnet damit den Weg für die Aufnahme von Patienten in den USAAUSTIN, Texas, June 15, 2026 (GLOBE... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 4,554 | +3,08 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S | WASHINGTON, July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 8,540 | +3,39 % | Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA (arimoclomol) in Niemann-Pick Disease Type C (NPC) | ||
| SPERO THERAPEUTICS | 1,011 | -1,08 % | Spero Announces Royalty Financing Deal With Affiliates Of Healthcare Royalty | LONDON (dpa-AFX) - Spero Therapeutics (SPRO) announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, or HCRx, a royalty acquisition... ► Artikel lesen |
Das Unternehmen XILIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,090 (+0,99 %) liegt der Kurs bei 9,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.